Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Miles, Sarah L ^a   Fischer, Adam P ^a   Joshi, Sandeep J ^b   Niles, Richard M ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Ascorbate 2 phosphate; Ascorbic acid; Hypoxia inducible factor 1 alpha; Melanoma; Prolyl hydroxylase

Indexed keywords

ASCORBIC ACID; ASCORBIC ACID 2 PHOSPHATE; FACTOR INHIBITING HIF; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN PHD2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ASCORBATE-2-PHOSPHATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; GENE ACTIVITY; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTATIC MELANOMA; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STABILITY; REPORTER GENE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL HYPOXIA; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ASCORBIC ACID; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; NEOPLASM METASTASIS; PROTEIN STABILITY; TRANSCRIPTION, GENETIC;

EID: 84946400605     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1878-5     Document Type: Article

References (53)

1. Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Ups J Med Sci. 2012;117(2):237-43. doi: 10.3109/03009734.2012.658977.
2. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65(5):1032-47. doi: 10.1016/j.jaad.2011.04.031.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998-1012. doi: 10.1056/NEJMra041245.
4. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000;19(1):21-34.
5. Berrocal A, Cabanas L, Espinosa E, Fernandez-de-Misa R, Martin-Algarra S, Martinez-Cedres JC et al. Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in therapy. 2014. doi:10.1007/s12325-014-0148-2
6. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002;8(10):3075-81.
7. Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother. 2013;47(4):519-26. doi: 10.1345/aph.1R614.
8. Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA. Current management of advanced melanoma: a transformed landscape. ANZ J Surg. 2014;84(9):612-7. doi: 10.1111/ans.12673.
9. Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther. 2002;1(1):14-7.
10. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 2008;21(1):27-38. doi: 10.1111/j.1755-148X.2007.00433.x.
11. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res. 2006;66(16):7833-6. doi: 10.1158/0008-5472.can-06-0731.
12. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667-72.
13. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003;278(33):30772-80. doi: 10.1074/jbc.M304982200.
14. Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2006;16 Suppl 1:405-12. doi: 10.1111/j.1525-1438.2006.00310.x..
15. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-related cancer. 2006;13(3):739-49. doi: 10.1677/erc.1.00728.
16. Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. British journal of cancer. 2011;104(1):166-74. doi: 10.1038/sj.bjc.6606020.
17. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Internal medicine (Tokyo, Japan). 2002;41(2):79-83.
18. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. European journal of cancer (Oxford, England: 1990). 2010;46(6):1159-69. doi: 10.1016/j.ejca.2010.01.031.
19. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma research. 2003;13(5):493-501. doi: 10.1097/01.cmr.0000056268.56735.4c.
20. Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M et al. Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clinical and experimental dermatology. 2009;34(8):e962-4. doi: 10.1111/j.1365-2230.2009.03706.x.
21. Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment cell & melanoma research. 2009;22(2):166-74. doi: 10.1111/j.1755-148X.2009.00553.x.
22. Goda N, Dozier SJ, Johnson RS. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxidants & redox signaling. 2003;5(4):467-73. doi: 10.1089/152308603768295212.
23. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research. 1999;59(22):5830-5.
24. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-43. doi: 10.1038/sj.onc.1203938.
25. Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Molecular cancer. 2009;8:104. doi: 10.1186/1476-4598-8-104.
26. Zbytek B, Peacock DL, Seagroves TN, Slominski A. Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermato-endocrinology. 2013;5(2):239-51. doi: 10.4161/derm.22678.
27. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug discovery today. 2007;12(19-20):853-9. doi: 10.1016/j.drudis.2007.08.006.
28. Kuiper C, Dachs GU, Munn D, Currie MJ, Robinson BA, Pearson JF et al. Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer. Frontiers in oncology. 2014;4:10. doi: 10.3389/fonc.2014.00010.
29. Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer research. 2010;70(14):5749-58. doi: 10.1158/0008-5472.can-10-0263.
30. Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World journal of gastroenterology: WJG. 2005;11(3):403-6.
31. Schleich T, Rodemeister S, Venturelli S, Sinnberg T, Garbe C, Busch C. Decreased plasma ascorbate levels in stage IV melanoma patients. Metabolism and Nutrition in Oncology. 2013(EFirst).
32. Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H et al. High levels of oxidative stress in patients with advanced lung cancer. Respirology (Carlton, Vic). 2008;13(1):112-6. doi: 10.1111/j.1440-1843.2007.01212.x.
33. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochemical and biophysical research communications. 1998;247(1):166-70. doi: 10.1006/bbrc.1998.8752.
34. Bhagat SS, Ghone RA, Suryakar AN, Hundekar PS. Lipid peroxidation and antioxidant vitamin status in colorectal cancer patients. Indian journal of physiology and pharmacology. 2011;55(1):72-6.
35. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(8):3704-9.
36. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Advances in nutrition (Bethesda, Md). 2011;2(2):78-88. doi: 10.3945/an.110.000109.
37. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T et al. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. The Journal of clinical investigation. 2013;123(5):2078-93. doi: 10.1172/jci66715.
38. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer cell. 2008;13(6):472-82. doi: 10.1016/j.ccr.2008.05.005.
39. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6(2):155-76. doi: 10.1016/j.molonc.2012.02.004.
40. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003;63(8):1764-8.
41. Kuiper C, Dachs GU, Currie MJ, Vissers MC. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response. Free Radic Biol Med. 2014;69:308-17. doi: 10.1016/j.freeradbiomed.2014.01.033.
42. Vissers MC, Gunningham SP, Morrison MJ, Dachs GU, Currie MJ. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med. 2007;42(6):765-72. doi: 10.1016/j.freeradbiomed.2006.11.023.
43. Nagao N, Nakayama T, Etoh T, Saiki I, Miwa N. Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. Journal of cancer research and clinical oncology. 2000;126(9):511-8.
44. Liu JW, Nagao N, Kageyama K, Miwa N. Anti-metastatic effect of an autooxidation-resistant and lipophilic ascorbic acid derivative through inhibition of tumor invasion. Anticancer research. 2000;20(1a):113-8.
45. Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996;34(1):29-33.
46. Sasaki T, Majamaa K, Uitto J. Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action. The Journal of biological chemistry. 1987;262(19):9397-403.
47. Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, Kivirikko KI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. The Journal of biological chemistry. 1986;261(17):7819-23.
48. Wang J, Buss JL, Chen G, Ponka P, Pantopoulos K. The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS letters. 2002;529(2-3):309-12.
49. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. The EMBO journal. 2003;22(16):4082-90. doi: 10.1093/emboj/cdg392.
50. Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008;111(6):3229-35. doi: 10.1182/blood-2007-09-114561.
51. Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. Journal of cell science. 2003;116(Pt 7):1319-26.
52. Malavolti M, Malagoli C, Fiorentini C, Longo C, Farnetani F, Ricci C et al. Association between dietary vitamin C and risk of cutaneous melanoma in a population of Northern Italy. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2013;83(5):291-8. doi: 10.1024/0300-9831/a000171.
53. Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT et al. Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. Journal of translational medicine. 2014;12:127. doi: 10.1186/1479-5876-12-127.